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Results Most patients had dramatic but transient reduc-
tion in circulating blasts; however, no remissions were 
achieved on this schedule. The most common toxicities 
were gastrointestinal, fatigue, transaminitis, and clinical 
and laboratory manifestations of tumor lysis syndrome, 
including one patient who died of acute renal failure. 
Dinaciclib pharmacokinetics showed rapid (2 h) achieve-
ment of maximum concentration and a short elimination/
distribution phase. Pharmacodynamic studies demonstrated 
in vivo inhibition of Mcl-1 expression and induction of 
PARP cleavage in patients’ peripheral blood mononuclear 
cells 4 h after dinaciclib infusion, but the effects were lost 
by 24 h and did not correlate with clinical outcome. Cor-
relative in vitro studies showed that prolonged exposures to 
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dinaciclib, at clinically attainable concentrations, result in 
improved leukemia cell kill.
Conclusions While dinaciclib given as a 2-h bolus did not 
exhibit durable clinical activity, pharmacokinetic and phar-
macodynamic data support the exploration of prolonged 
infusion schedules in future trials in patients with acute 
leukemias. 
Keywords Dinaciclib · Acute leukemia ·  
Cyclin-dependent kinase · CDK inhibitor · Mcl-1
Introduction
Uncontrolled proliferation and deregulated cell cycle pro-
gression are hallmarks of many human cancers, including 
acute leukemias. Cyclin-dependent kinases (CDKs) are 
serine/threonine kinases that primarily regulate the mam-
malian cell cycle and thus represent an appealing thera-
peutic target [1–3]. However, progression through the 
cell cycle is a complex process that depends on synchro-
nized activity of different CDKs (CDK1, CDK2, CDK4, 
CDK6), their phosphorylation status, and association with 
cyclins and endogenous Cip/Kip or INK4 inhibitors [4–7]. 
Alteration in any of these components may lead to cell 
cycle arrest and/or apoptosis or, as seen in cancer cells, 
to unregulated cellular proliferation [2, 3]. Besides con-
trolling cell cycle, several members of CDK family have 
specific cell cycle-independent effects. CDK5 is known to 
play a role in neuronal function and cellular senescence 
[8], while CDK7/cyclin H and CDK9/cyclin T complexes 
modulate cellular transcription through phosphorylation of 
the COOH-terminal domain (CTD) of RNA polymerase 
II [9–12]. Inhibition of transcriptional CDKs may induce 
cell death through down-regulation of several short-lived 
proteins, including the anti-apoptotic proteins Mcl-1 and 
XIAP [13–16].
Given the key role of CDKs in both cell cycle regula-
tion and cellular transcription processes which are fre-
quently altered in malignant cells, several small-molecule 
CDK inhibitors with a broad but not completely overlap-
ping CDK inhibitory activity have been developed and 
tested clinically as anti-cancer agents (flavopiridol, SNS-
032, seliciclib, AT7519, PHA-793887) [17, 18]. Flavopiri-
dol was the first in this class to enter the clinical arena 
and has shown promising single-agent clinical activity 
in patients with high-risk chronic lymphocytic leuke-
mia (CLL), but also toxicity associated with its narrow 
therapeutic index [19, 20]. While flavopiridol displayed 
limited single-agent activity in patients with acute leuke-
mia [21], when given in timed sequence with cytarabine 
and mitoxantrone (FLAM regimen), an approach based 
on pre-clinical in vitro modeling in leukemia cells [22], 
direct anti-leukemia cytotoxicity and encouraging clinical 
responses were observed in patients with poor-risk newly 
diagnosed and relapsed/refractory acute myeloid leukemia 
(AML) [23–26].
Dinaciclib is a novel potent CDK1, CDK2, CDK5, and 
CDK9 inhibitor (IC50 1–4 nM) that was found to have a 
superior therapeutic index (TI; maximum tolerated dose to 
effective dose) in comparison both SNS-032 and flavopiri-
dol (TI of 10 vs. 2 vs. <1, respectively) in a pre-clinical in 
vivo screen using an A2780 ovarian carcinoma xenograft 
mouse model [27]. Compared with flavopiridol, dinaci-
clib appears to be an equally potent inhibitor of CDK1 and 
CDK9, but a much stronger inhibitor of CDK2 and CDK5, 
and more selective in an in vitro kinase screen [27]. Pre-
clinical studies have also demonstrated that dinaciclib is a 
potent growth inhibitor (median IC50, 11 nM) and inducer 
of apoptosis in a variety of human cell lines, including leu-
kemia cells and xenograft models [27–30]. Based on these 
findings and the direct cytotoxic effect of flavopiridol in 
vivo, we hypothesized that dinaciclib might be useful to 
treat patients with acute leukemias.
Two phase I clinical studies explored the activity of 
dinaciclib given as a 2-h infusion on days 1, 8, 15 every 
28 days [31] or once every 21 days [32] to patients with 
solid tumors. The recommended phase II doses (RPTD) 
were 12 and 50 mg/m2, respectively. The primary dose-
limiting toxicities (DLT) were sepsis, hyperuricemia, and 
hypotension with the weekly schedule and neutropenia and 
transient liver function test (LFT) abnormalities with the 
every 21-day schedule. Based on these toxicity profiles, the 
latter dose/schedule was selected for testing in acute leuke-
mia patients. We report our initial clinical experience with 
dinaciclib in patients with advanced AML and acute lym-
phoid leukemia (ALL), along with correlative pharmacoki-
netic (PK) and pharmacodynamic studies. We also present 
observations prompted by our clinical and pharmacological 
findings that, in turn, will inform further development of 
dinaciclib in acute leukemias.
Materials and methods
Study design and patients
This was a phase II multi-center study (NCT00798213) 
of dinaciclib that was originally designed as a randomized 
study for relapsed and/or refractory AML patients com-
paring the efficacy of dinaciclib versus gemtuzumab ozo-
gamicin (GO, Mylotarg) and a single-arm study of dinaci-
clib in patients with ALL. AML patients treated with GO 
could cross over to dinaciclib at the time of disease pro-
gression. The study was approved by the Institutional 
Review Board (IRB) at each participating institution and 
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was conducted in accordance with the Declaration of Hel-
sinki and in compliance with International Conference on 
Harmonization Good Clinical Practice Guidelines. Writ-
ten informed consent was obtained from all patients before 
study enrollment.
Patients with CD33-expressing AML (≥60 years old) or 
with ALL (≥18 years old) in first or second relapse or hav-
ing primary refractory disease or refractory disease after 
first salvage and not considered candidates for hematopoi-
etic stem cell transplantation (HSCT) were eligible for the 
study, provided they had an Eastern Cooperative Oncology 
Group (ECOG) performance status of ≤1, white blood cell 
(WBC) count ≤30 × 109/L, serum creatinine ≤2 mg/dL, 
alanine aminotransferase (ALT) or aspartate aminotrans-
ferase (AST) ≤2.5 X upper limit of normal and normal 
bilirubin. Patients were ineligible if they had active central 
nervous system disease, a second malignancy requiring 
treatment, known HIV, hepatitis B or hepatitis C infec-
tion, previous GO or CDK inhibitor treatment, or previous 
HSCT.
This study was initiated on March 10, 2009. Results were 
analyzed as of June 21, 2011. The study was terminated 
after enrollment of 26 patients due to change in the study 
sponsor; however, a total of 20 patients received dinaciclib 
(2 patients crossed over from GO), and the clinical experi-
ence with dinaciclib in these patients is presented below.
Study objectives and treatment plan
The primary objective was to determine the overall 
response rate (ORR), and secondary objectives included 
time to progression (TTP), safety, dinaciclib PKs, and 
exploratory biomarker studies.
Dinaciclib 50 mg/m2 was given as a 2-h intravenous (IV) 
infusion in cycle 1, and if well tolerated, intra-patient dose 
escalation to 70 mg/m2 was allowed in cycle 2. Each cycle 
lasted 21 days. Patient could continue treatment on the 
study in the absence of disease progression or unacceptable 
toxicity. The next cycle of therapy could start if non-hema-
tologic toxicity from previous cycle recovered to ≤grade 1, 
and dose delay of up to 3 weeks was allowed for recov-
ery. Permanent dose reduction was required for any ≥grade 
3 clinically significant non-hematologic adverse event 
(70 mg/m2 → 50 mg/m2; 50 mg/m2 → 40 mg/m2; 40 mg/
m2 → 30 mg/m2; 30 mg/m2 → discontinue). To allow for 
continued treatment of subjects whose cytopenias were 
due to leukemia and not due to drug toxicity, subsequent 
cycles of treatment were allowed if absolute neutrophil 
count (ANC) ≥0.5 × 109/L or for ANC <0.5 × 109/L but 
no more than 20 % below the baseline pretreatment levels 
and platelet count ≥20 × 109/L or platelets <20 × 109/L 
but no more than 20 % below the baseline pretreatment lev-
els. Anti-emetic prophylaxis including serotonin-receptor 
antagonist, metoclopramide, or prochloperazine with or 
without dexamethasone was allowed. After 10 patients had 
been treated with dinaciclib, the protocol was amended to 
require hospitalization for cycle 1 treatment, with adminis-
tration of pre-treatment rasburicase, allopurinol, hydration, 
phosphate binders, and early administration of Kayexalate 
(sodium polystyrene sulfonate) for hyperkalemia, including 
pre-treatment for potassium ≥4 mmol/L. Intense monitor-
ing of laboratory parameters for evidence of tumor lysis 
syndrome was required, including repeat measurements of 
serum potassium at 1, 2, 3, 6, and 24 h after start of dinaci-
clib infusion or more frequently if needed. Dexamethasone 
20 mg IV was given early if symptoms of cytokine release 
syndrome were observed [19].
Response and toxicity evaluation
Response was assessed by bone marrow (BM) examination 
on day 21 of cycles 1 and 2, and every 6 weeks thereaf-
ter until complete remission or progressive disease (PD). 
Response was determined according to the revised rec-
ommendations of the International Working Group (IWG) 
for AML [33]. Toxicities were graded according to the 
National Cancer Institute Common Terminology Criteria 
for Adverse Events (NCI CTCAE), version 3.0 (http://ctep.
cancer.gov/protocolDevelopment/electronic_applications/
docs/ctcaev3.pdf). Hematologic and chemistry profiles 
were monitored on day 1 and 2 of each cycle or until reso-
lution of acute toxicities and subsequently at least once 
a week or more frequently depending on the individual 
patient’s needs.
Pharmacokinetic analysis
Blood samples for PK evaluations (3 mL each) were col-
lected into prechilled K2 EDTA tubes at 0, 0.25–0.5, 1–2, 
and 4 h after the end of the 2-h infusion on day 1 of cycles 
1, 2, and 3. Samples were kept on ice and centrifuged 
within 1 h of collection at 2,700g/4 °C for 10 min; sepa-
rated plasma was immediately frozen on dry ice and then 
stored at −20 °C or below.
Dinaciclib plasma concentrations were determined using 
a validated high-performance liquid chromatography assay 
with tandem mass spectrometry detection [34]. The internal 
standard was [13C3]-dinaciclib. The lower limit of quan-
titation (LLOQ) was 0.0250 ng/mL and the upper limit of 
quantitation was 10.0 ng/mL. The accuracy at the LLOQ 
was −1.0 and the precision coefficient of variation (CV) 
was 10.6 %. The accuracy at low, medium, and high quality 
control (QC) concentration was 5.8, 5.7, and 2.7, respec-
tively, and precision at low, medium, and high QC concen-
trations was 4.9, 4.0, and 4.2, respectively. Dilution integ-
rity was demonstrated at 10,000 ng/mL.
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Plasma concentration versus time profiles and sys-
temic exposure of dinaciclib in this study were estimated 
using a population pharmacokinetic (PPK) model-based 
approach. A 2-compartment PPK model was developed 
with data from two phase I studies in solid tumors [31, 32]. 
The model fits were conducted using NONMEM V, level 
1.1 (GloboMax LLC), and a first-order conditional estima-
tion method was employed for all model runs. The model 
included between-subject variability on clearance and vol-
ume of distribution, and mixed error terms.
Pharmacodynamic analysis on primary patient’ samples
Peripheral blood (PB) samples, ≈20 cc/time point, were 
collected pre-treatment, and 4 and 24 h after the end of the 
dinaciclib infusion in cycle 1 in patients who had PB blasts 
≥3 × 109/L for whom a laboratory facility was available 
for immediate specimen processing. For Western blot anal-
ysis, PB mononuclear cells (PBMC) were isolated by gra-
dient centrifugation using lymphocyte separation medium 
(LSM) (Mediatech Inc., Manassas, VA, USA), and protein 
extracts were prepared and analyzed for the expression of 
Mcl-1, phospho-Rb (Ser807/811), and PARP cleavage as 
described below.
In vitro studies on primary leukemia cells and human 
leukemia cell lines
Primary leukemia cells for in vitro studies were isolated from 
BM or PB obtained from AML or ALL patients enrolled on 
a separate University of Maryland, Baltimore, IRB-approved 
protocol for tissue collection and not treated on this clini-
cal study. The cells were isolated by gradient centrifugation 
using LSM (Mediatech) according to the manufacturer’s 
protocol. Cells were used either fresh or after viable freezing 
(FBS/10 % DMSO). Primary leukemia cells were cultured 
in RPMI 1640 (Invitrogen, Grand Island, NY, USA) supple-
mented with 15 % heat-inactivated FBS (HyClone Labora-
tories Inc., Red Bank, NJ, USA) and 200 mM l-Glutamine 
(Invitrogen). Leukemia cell lines HL-60 (AML), MOLT-4 
(T cell ALL), and K562 (chronic myelogenous leukemia 
[CML] in erythroid blast transformation) were purchased 
from American Type Culture Collection (ATCC, Manassas, 
VA, USA) and cultured in RPMI 1640 (Invitrogen) supple-
mented with 10 % heat-inactivated FBS (HyClone Laborato-
ries Inc.) and 200 mM l-Glutamine (Invitrogen).
Dinaciclib (SCH727965) was obtained from Merck & 
Co. Inc., Whitehouse Station, NJ, USA (originally Scher-
ing-Plough, Kenilworth, NJ, USA). The drug was dissolved 
in DMSO at 20 mM, aliquoted, and stored at −20 °C until 
use. Z-VAD-FMK (BD Parmingen, San Diego, CA, USA), 
a pancaspase inhibitor, was dissolved in DMSO at 20–
60 mM and stored in aliquots at −20 °C until use.
Cell proliferation after dinaciclib treatment was assessed 
using the WST-1 cell proliferation assay (Roche, Indian-
apolis, IN, USA). Primary leukemia cells were cultured in 
the presence of increasing concentrations of the dinaciclib 
(0.0004–10 μM) for 24 h. Leukemia cells lines (HL-60, 
MOLT-4, K562) were cultured in the presence of increas-
ing concentrations of the dinaciclib (0.0004–10 μM) for 
2–72 h. Cells cultured in the presence of an equivalent vol-
ume of DMSO served as a treatment control. 4–8 replicates 
were plated for each drug dilution or control. The IC50 val-
ues for the WST-1 assay were calculated using GraphPad 
Prism 5 software (La Jolla, CA, USA).
Apoptosis assay was performed on fresh primary leu-
kemia cells and leukemia cell lines (HL-60 and K562) 
treated with dinaciclib (2–200 nM) or an equivalent volume 
of DMSO (control) for different lengths of time (2–24 h). 
After treatment, cells were washed twice with cold PBS, 
resuspended in 1X binding buffer, and stained with pro-
pidium iodide (PI) and Annexin V using a FITC Annexin 
V Apoptosis Detection Kit I (BD Pharmingen) according 
to the manufacturer’s instructions. The stained cells were 
evaluated within 1 h on a FACScan (BD Biosciences, San 
Jose, CA, USA) and analyzed using FlowJo software (Tree 
Star, Ashland, OR, USA).
For cell cycle analysis, leukemia cells (HL-60 and 
K562) were treated with dinaciclib (20 and 200 nM) for 
2–24 h, pelleted, fixed in 70 % ethanol at −20 °C, stained 
with 500 μl PI/RNase staining buffer (BD Pharmingen), 
and analyzed using a FACScan (BD Bioscience) and 
FlowJo software (Tree Star).
For Western blot analysis, leukemia cell pellets (pri-
mary leukemia cells, HL-60, MOLT-4, K562) were washed 
with PBS and lysed with RIPA buffer (Sigma-Aldrich, St. 
Louis, MO, USA) supplemented with Complete Mini™ 
protease inhibitor and PHOStop™ phosphatase inhibitors 
(Roche). Equal amounts of proteins up to 25 μg were sep-
arated on 4–12 % NuPAGE precast gels in 1X MOPS or 
1X MES buffer (Invitrogen) and electro-blotted to PVDF 
membranes (Millipore, Billerica, MA, USA). The mem-
branes were blocked with 5 % dry milk in 1X TBS/0.1 % 
Tween 20 for at least 1 h at room temperature. Blots were 
incubated with primary antibody (Ab) overnight at 4 °C, 
washed 3 times in TBS/0.1 % Tween 20, and then incu-
bated with secondary Ab for 1 h at room temperature. Blots 
were washed three times, and the signal was detected with 
Amersham™ ECL™ detection systems (GE Healthcare, 
Pittsburgh, PA, USA). The following primary Abs were 
used: mouse anti-PARP (BD Pharmingen), rabbit anti-
phospho-Rb (Ser807/811) and rabbit anti-Mcl-1 (both from 
Santa Cruz, Santa Cruz, CA, USA), rabbit anti-caspase 9 
p35 and anti-caspase 3 (both from Cell Signaling, Dan-
vers, MA, USA), and mouse anti-β-actin (Sigma-Aldrich). 
Commercially available HL-60 cell extract, non-induced 
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SW-101 and etoposide-induced SW-102, were used as neg-
ative and positive controls for PARP cleavage (Enzo Life 
Sciences, Plymouth Meeting, PA, USA). Secondary horse-
radish peroxidase-conjugated anti-mouse or anti-rabbit 
Abs were from Cell Signaling (Beverly, MA, USA). The 
Western blot signals were measured by densitometry using 
ImageJ 1.45I software (NIH, Bethesda, USA).
Statistics
The primary efficacy endpoint of the study was the ORR, 
including complete remission (CR), CR with incomplete 
count recovery (CRi), and partial remission. The second-
ary efficacy endpoint was TTP, defined as the time from the 
date of randomization (AML)/enrollment (ALL)/first dose 
of dinaciclib (AML crossed over from GO) to the first date 
of documented PD or death due to PD.
Results
Patient characteristics
Between March 2009 and April 2010, a total of 26 patients 
were enrolled on this phase II study. Twenty patients with 
advanced acute leukemia received dinaciclib (2 patients 
crossed over from GO) and their characteristics are detailed 
in Table 1. Most patients treated with dinaciclib had AML 
(70 %), were 60 years or older (85 %), and had disease 
refractory to prior therapies (80 %). Data on 8 patients 
treated with GO and statistical analyses on their outcomes 
are presented in the Online Tables S1 and S2a–c.
Toxicities
A total of 38 cycles of dinaciclib were given to 20 patients, 
with a median of 1 cycle per patient (range, 1–5). Eight 
of 10 patients were given dinaciclib 70 mg/m2 in cycle 
2, while one patient received dinaciclib 40 mg/m2 and 
another dinaciclib 50 mg/m2 in cycle 2 because of syn-
cope and cytokine release syndrome, respectively, in cycle 
1. Dinaciclib was dose-reduced to 50 mg/m2 in cycle 3 in 
an additional patient because of fatigue. Overall, 15 (75 %) 
patients treated with dinaciclib experienced grade ≥3 treat-
ment-related adverse events (AE) with hematologic toxici-
ties and fatigue being the most frequent. Though difficult 
to assess in a leukemia patient population, the most com-
mon dinaciclib-related ≥grade 3 hematologic toxicities 
included leukopenia (40 %), anemia (25 %), febrile neu-
tropenia (25 %), thrombocytopenia (20 %), and neutrope-
nia (10 %). Non-hematologic treatment-related adverse 
events (AE) occurring in ≥10 % patients are presented 
in Table 2. The most common non-hematologic toxicities 
were gastrointestinal, fatigue, and laboratory abnormalities, 
including electrolyte disturbances and transient transamini-
tis. Grade 1 and 2 diarrhea was common, occurring in 70 % 
of patients, with onset within hours after initiation of treat-
ment but usually resolved within a day. Grade ≥3 fatigue 
was noted in 4 (20 %) patients, while syncope that resolved 
without intervention was observed in the same patient in 
cycles 1 and 2. Overall, half of the patients had at least 
one significant tumor lysis syndrome (TLS)-associated 
Table 1  Characteristics of patients treated with dinaciclib





 No. (%) 17 (85)
Diagnosis
 AML, no. (%) 14 (70)
 ALL, no. (%) 6 (30)
Gender
 Male, no. (%) 14 (70)










 Complex (≥3 chromosomal abnormalities) 4
 Monosomy 7 2
 Trisomy 8 2
 Other chromosomal abnormalities 3
 Normal karyotype 3
ALL
 t(9;22) 2
 Other chromosomal abnormalities 3





 First relapse 4
 Primary refractory 11
 Refractory disease after salvage 5
Median WBC count ×106/L (range) 2,650 (400–17,200)
Median circulating blast count ×106/L (range) 627 (0–9,975)
Median bone marrow blast count, % (range) 54 (1.4–96)
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laboratory abnormality (defined by Cairo-Bishop crite-
ria) [35] in cycle 1, including hyperphosphatemia (30 %), 
hypocalcemia (25 %), hyperkalemia (25 %), and/or hyper-
uricemia (10 %). Three patients had clinical grade ≥3 TLS, 
manifesting as cardiac arrhythmia (1) and/or renal insuffi-
ciency (2), including a patient with AML who developed 
hyperacute TLS requiring hemodialysis and died of acute 
renal failure (ARF) on day 13 of cycle 1, despite intense 
pre-treatment prophylaxis with rasburicase, calcium ace-
tate, and sevelamer and aggressive treatment of TLS with 
insulin, calcium gluconate, and sodium polystyrene sul-
fonate. This patient had evidence of TLS even before 
treatment such as abnormal electrolytes, elevated creati-
nine, including history of chronic renal insufficiency, and 
required hydroxyurea for count control before study treat-
ment. We examined the association between the baseline 
and pre-treatment (day 1) measurements of total WBC 
count, peripheral blood blast count, % blast in the BM, uric 
acid, lactate dehydrogenase (LDH), and creatinine on the 
development of TLS. Despite the small sample size, we 
Table 2  Dinaciclib-related 
non-hematologic adverse events 
occurring in ≥2 (10 %) patients






All (%) Grade ≥3 All (%) Grade ≥3 All (%) Grade ≥3
Cardiovascular
 Hypertension 1 (5) − − − 1 (17) −
 Hypotension 6 (30) 1 2 (20) − − −
 Sinus Tachycardia 2 (10) − − − − −
Constitutional
 Cytokine release sy 2 (10) − − − 1 (17) 1
 Dehydration 1 (5) 1 1 (10) − − −
 Fatigue 6 (30) 2 2 (20) 1 1 (17) 1
Gastrointestinal
 Anorexia 1 (5) − − − 1 (17) −
 Diarrhea 14 (70) 1 7 (70) 1 2 (33) −
 Nausea 8 (40) 1 3 (30) − 1 (17) −
 Stomatitis 1 (5) − 1 (10) 1 − −
 Vomiting 9 (45) − 2 (20) − 2 (33) −
Hepatic
 Hyperbilirubinemia 2 (10) − 1 (10) − − −
 Increased ALT 4 (20) − 1 (10) − 1 (17) −
 Increased AST 8 (40) 3 1 (10) − − −
Infections
 Bacteremia 2 (10) 2 − − − −
 Pneumonia 2 (10) 2 1 (10) − − −
Metabolic and electrolyte abnormalities
 Hyperglycemia 4 (20) 2 − − − −
 Hyperkalemia 3 (15) 2 1 (10) − − −
 Hyperphosphatemia 5 (25) 1 1 (10) − − −
 Hypoalbuminemia 4 (20) − 1 (10) − − −
 Hypocalcemia 6 (30) 1 − − − −
 Hypokalemia 2 (10) − − − − −
 Hyponatremia 2 (10) 1 − − − −
 Increased LDH 2 (10) 2 − − − −
 Tumor lysis sy 3 (15) 3 − − − −
Neurology
 Syncope 1 (5) 1 1 (10) 1 − −
Renal
 Acute renal failure 2 (10) 2 − − − −
 Increased creatinine 3 (15) 1 − − − −
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found that higher pre-treatment creatinine might be asso-
ciated with the increased risk of developing TLS (Logistic 
Regression Wald test; p value = 0.0543). An additional 
9 patients died on study, 8 from PD and 1 from intracra-
nial hemorrhage due to disease-related thrombocytopenia. 
Of the remaining 10 patients, 9 were removed from study 
because of PD and 1 per patient request.
Clinical outcomes
No objective responses by IWG criteria were documented, 
but evidence of direct anti-leukemia cytotoxic activity 
manifesting as a temporary decrease in PB and/or marrow 
blasts was observed in 60 % of patients. Ten of 13 (77 %) 
patients with circulating blasts (7/7 AML; 3/6 ALL) had 
>50 % decrease in the absolute blast count (ABC) within 
1–8 days of the first dinaciclib dose, including 6 (46 %) 
with >80 % decrease. The median pretreatment WBC count 
for all patients was 2,650 × 106/L (range, 400–17,200 × 
106/L) and it declined to 1,045 × 106/L (range, 200–14,000 
× 106/L) and 1,350 × 106/L (range, 200–100,800 × 106/L) 
on days 2 and 8, respectively. The median duration of the 
WBC nadir was 5 (range, 0–7) days. The decline in WBC 
count during cycle 1 in patients with AML and ALL is pre-
sented in Fig. 1a, b, respectively. For patients with circu-
lating blasts, the median pre-treatment absolute blast count 
(ABC) was 1,130 × 106/L (range, 220–9,975 × 106/L), the 
median ABC nadir was 200 × 106/L (range, 0–1,350 × 
106/L), the median time to nadir was 3 (range, 1–16) days, 
and the duration of nadir was 7 (range, 1–24) days. Overall, 
b
d


















2 3 4 5 6 7
Shaded area: 90% CI
Solid Line: PPK Model 
Predicted Median 
Black Circles: Observed 
Concentrations
















Fig. 1  The effects of dinaciclib on circulating WBCs, pharmacoki-
netics, and pharmacodynamics. a Graph demonstrating rapid decline 
in the WBC count in AML patients after treatment with dinaciclib, 
followed by gradual recovery, usually by day 15. b Graph demon-
strating rapid decline in the WBC count in ALL patients after treat-
ment with dinaciclib. c Population pharmacokinetic (PPK) model-
based prediction of plasma concentration versus time profiles 
following a single 2-h infusion of 50 mg/m2 dinaciclib. d Western 
blot analysis of protein lysates obtained from PBMC collected prior 
to and at 4 and 24 h after dinaciclib infusion to measure the expres-
sion of p-Rb and Mcl-1 and induction of PARP cleavage. β-actin con-
trols are shown to document equivalent loading and transfer of pro-
teins. Lanes were loaded with 8–25 μg of protein
904 Cancer Chemother Pharmacol (2013) 72:897–908
1 3
8 of 13 patients who had follow-up BM evaluations had an 
average of 36 % (range, 6–67 %) reduction in BM blasts 
in the course of treatment, with 2 patients achieving >50 % 
blast reduction in the marrow (1 on day 21 and 1 on day 
42).
For AML patients included in the initial randomization, 
median TTP was 5.14 (range, 1.57–13.14) weeks, and for 
ALL patients, TTP ranged from 1 to 8.14 weeks. Two AML 
patients who crossed over from GO had TTP of 7.86 and 
9.14 weeks, respectively.
Pharmacokinetics
PK data were available from all 20 patients. Observed 
plasma concentrations are summarized in Table 3. Plasma 
concentrations predicted from the PPK model correlated 
with the observed values. Additionally, the model param-
eter estimates with and without inclusion of data from 
the current study are similar. This indicates that the PPK 
model-based approach can be used to estimate the pharma-
cokinetics of dinaciclib in this study.
As shown in Fig. 1c, the observed plasma concentrations 
collected at sparse sampling times are within 90 % confi-
dence interval of model-predicted values. Thus, based on 
the model-predicted PK profile, the estimated mean AUC 
values at doses of 50 mg/m2 and 70 mg/m2 are 3,556 ng 
h/mL (CV% = 15) and 4,979 ng h/mL, respectively. The 
AUC values estimated in this study are similar to those 
observed previously in phase I studies [31, 32].
Pharmacodynamics
Pre-treatment, 4- and 24-h post-end of infusion samples 
of PBMC were obtained from 1 AML and 3 ALL patients. 
We examined the in vivo effects of dinaciclib on the inhibi-
tion of serine 807 and 811 phosphorylation of the Rb pro-
tein, as a readout for CDK1 and CDK2 inhibition, and on 
the expression of Mcl-1, a short-lived anti-apoptotic pro-
tein, as an indirect measure of the ability of dinaciclib to 
repress transcription through the inhibition of CDK9. We 
also examined whether treatment with dinaciclib leads to 
induction of PARP cleavage, indicating apoptotic cell death. 
As depicted in Fig. 1d, decrease in Mcl-1 was seen in all 
specimens at 4-h post-treatment, concordant with inhibi-
tion of CDK9, but the expression of Mcl-1 returned to base-
line by 24 h, suggesting that the inhibition was lost by that 
time. Induction of PARP cleavage was also observed at 4 h, 
although in one specimen PARP cleavage product was high 
at baseline. Decline in p-Rb was observed in 1 patient, while 
2 patients had almost undetectable p-Rb levels at baseline.
In vitro studies on primary leukemia cells
The clinical and pharmacodynamic data prompted further 
studies in leukemia cell lines and primary leukemia cells. 
As presented in Online Fig. S1a–c, we were able to demon-
strate that prolonged exposures (24 or 72 vs. 2 h) to dinaci-
clib concentrations attainable in vivo have a more potent 
growth inhibitory and apoptosis-inducing effect across 
different leukemia cell lines (HL-60, MOLT-4, K562). We 
have also demonstrated that dinaciclib down-regulates the 
expression of the anti-apoptotic protein Mcl-1 indepen-
dently of caspases and induces PARP cleavage in leukemia 
cell lines; however, these effects were most prominent with 
prolonged exposures (6 and 24 h) (Online Fig. S2a–b). A 
2-h exposure to dinaciclib was sufficient to induce down-
regulation of Mcl-1 and PARP cleavage only in the HL-60 
cell line; interestingly, and in agreement with in vivo data, 
this effect was lost by 24 h. Down-regulation of p-Rb was 
also observed in 2 of 3 cell lines.
Thus, we next examined the effect of prolonged dinaci-
clib exposure on primary leukemia cells. Figure 2a dem-
onstrates that treatment with dinaciclib for 24 h produced 
similar growth inhibitory effects across primary AML 
samples with different cytogenetic and molecular findings 
(Table 4) as measured by the WST-1 assay, with IC50 val-
ues in the range of those observed for leukemia cell lines 
(IC50 0.008–0.017 μM) and achievable in vivo. Dinaciclib 
induced apoptosis in primary AML cells (AML 08) in a 
time- and concentration-dependent manner, as measured 
Table 3  Mean (CV %) plasma 
concentrations of dinaciclib 2-h 
infusion (cycle 1–3)
CV coefficient of variation, 
NA not applicable (no sample 
collected)
a
 Combined data from cycles 1, 
2, and 3 for each dose level
b
 Time after the initiation of the 
dinaciclib infusion
Dose Plasma concentration (ng/mL)a
40 mg/m2  
(cycle 2, n = 1)
50 mg/m2 (cycle 1, n = 20;  
cycle 2, n = 1; cycle 3, n = 2)
70 mg/m2 (cycle 2, 
n = 8; cycle 3, n = 3)
Timeb (hours) Mean (ng/mL) Mean (ng/mL) CV % Mean (ng/mL) CV %
2 1,010 1,130 39 1,700 48
2.25 1,100 707 68 724 20
2.5 NA 354 52 457 87
3 NA 195 55 307 22
4 118 139 47 125 32
6 42.4 36.7 41 52.2 40
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Fig. 2  Prolonged exposure to dinaciclib effectively inhibits prolifera-
tion, induces apoptosis, and down-regulates Mcl-1 and phospho-Rb 
expression in primary leukemia cells. a Six primary AML samples 
were exposed to DMSO (control) or dinaciclib (0.0004–10 μM) for 
24 h and the IC50 values were estimated using the WST-1 assay. b 
Primary AML cells (AML 08) were exposed to dinaciclib (2, 20, and 
200 nM) for the indicated times and the extent of cell death was mon-
itored by measuring Annexin V/PI staining by flow cytometry. c Five 
primary AML and ALL samples were exposed to DMSO (control) 
and dinaciclib (20 and 200 nM) for 6 and/or 24 h, after which whole 
cells were lysed and proteins extracted, and subjected to Western blot 
analysis to measure the expression of PARP, Mcl-1, p-Rb. β-actin 
controls are shown to document equivalent loading and transfer of 
proteins. Lanes were loaded with 8–25 μg of protein
Table 4  Characteristics of primary leukemia cells for in vitro studies
FLT3 FMS-like tyrosine kinase 3, NMP1 nucleophosmin 1, MDS myelodysplastic syndrome, ET essential thrombocytosis, WT wild type, ND 
not done, ITD internal tandem duplication, MUT mutated, BM bone marrow, PB peripheral blood
Patient samples Diagnosis Disease status Cytogenetics FLT3 NPM1 Source % Blast
AML 01 AML arising  
from MDS
Status post-azacitidine  
for MDS
t(3;21), +8 WT ND BM 8
AML 02 AML post-ET Untreated Del (20q),
t(1;19) (q25;q13.3)
WT WT BM 21
ALL 03 ALL First relapse Normal ND ND PB 60
AML 04 AML Primary refractory Normal WT WT BM 25
AML 05 AML Untreated Inv(16) WT WT BM 61
AML 06 AML Untreated Normal D835 MUT PB 90
AML 07 AML Untreated Normal ITD ND BM 78
AML 08 AML Untreated Normal WT MUT BM 73
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by flow cytometric analysis of AnnexinV/PI staining 
(Fig. 2b). Similarly, down-regulation of Mcl-1 and induc-
tion of PARP cleavage were observed in all 5 primary leu-
kemia samples after 6-h exposure to dinaciclib (≥20 nM), 
but more prominent effects were noted at the 200 nM con-
centration and with 24-h exposure (Fig. 2c). The effects of 
dinaciclib on p-Rb expression were less consistent. While 
in 3 of 5 primary cell samples dinaciclib treatment resulted 
in down-regulation of p-Rb at 6 h, in 2 of the samples 
the level of p-Rb remained the same (AML 02) or even 
increased (AML 06), followed by complete inhibition of 
p-Rb at 24 h. Thus, data with cell lines and primary leuke-
mia cells are consistent and strongly suggest that prolonged 
exposures to dinaciclib, at clinically attainable concentra-
tions, should result in improved leukemia cell kill.
Discussion
Single-agent dinaciclib 50 mg/m2 given as a 2-h infusion 
has potent, but short-lived, cytoreductive activity, without 
objective responses observed in our patients with advanced 
acute leukemia. Dinaciclib administration was associated 
with frequent occurrence of diarrhea and tumor lysis mani-
festations, suggesting that dinaciclib shares the toxicity 
profile of other CDK inhibitors in leukemia patients [21, 
23–26, 36]. Pharmacodynamic data demonstrated a rapid 
decrease in Mcl-1 protein levels and induction of PARP 
cleavage in patients’ peripheral blood leukemia cells upon 
dinaciclib treatment, but with quick recovery once dinaci-
clib level declines. Further, in vitro studies on leukemia 
cells suggest that longer exposures to dinaciclib, at clini-
cally achievable concentrations, have a potent cytotoxic 
effect. Prolonged infusion schedules of dinaciclib adminis-
tration should be explored in future trials in acute leukemia.
In this study, we observed >50 % reduction in the cir-
culating blast count within 8 days of dinaciclib adminis-
tration in 77 % of patients; however, the nadir was short 
(≤1 week). The effect of dinaciclib on the BM blast con-
tent was modest, but, due to the timing of follow-up mar-
row examination, we might have missed the maximum 
effect. Despite difficulties in comparing phase I/II studies 
with different agents, single-agent dinaciclib appears to 
have cytoreductive activity similar to that of flavopiridol. 
Flavopiridol administered on a hybrid schedule [21] or as 
1-h bolus [25] for 3 days produced a >50 % decrease in 
WBC count in approximately 83 and 44 % of acute leu-
kemia patients, respectively, but the short duration of the 
nadir and the lack of measurable BM response to single-
agent flavopiridol were similar to our experience with 
dinaciclib [21].
The side effects observed after dinaciclib administration 
in this study appear very similar to those described for CLL 
patients receiving dinaciclib on a weekly schedule [37] 
and resemble toxicities seen with flavopiridol in leukemia 
patient populations [21, 23–26]. There was no difference 
between the 50 and 70 mg/m2 doses. The most frequent 
toxicities included transient gastrointestinal toxicities, LFT 
abnormalities, fatigue, and hypotension. Electrolyte abnor-
malities associated with tumor lysis were noted in at least 
50 % of patients, with 3 patients developing clinical TLS, 
including one who died of acute renal failure. Thus, intense 
monitoring of laboratory parameters and early intervention 
to abate the manifestations of TLS are necessary for the 
safe administration of this drug to acute leukemia patients.
We performed limited PK analysis in this study; how-
ever, the partial PK profile observed in our patients appears 
similar to those obtained in studies with more extensive PK 
profiling [31, 32, 34] and can be predicted using the PPK 
approach. Overall, dinaciclib exhibits linear PK, with dose-
related (50 → 70 mg/m2) increases in exposure (Cmax, 
AUC) and moderate inter-patient variability. The Cmax 
was achieved within 2 h and, following the end of infusion, 
dinaciclib was rapidly eliminated. Our pharmacodynamic 
Western blot studies showed that in vivo administration of 
dinaciclib led to down-regulation of Mcl-1 (34–76 %) and 
induction of PARP cleavage in PBMC sampled 4 h follow-
ing the end of the infusion in all 4 specimens examined, 
but Mcl-1 levels returned to baseline at 24 h, indicating that 
the surviving cells were able to recover. Down-regulation 
of Mcl-1 was also observed after dinaciclib treatment in 
CLL patients [37]; however, while serving as a pharmaco-
dynamic marker of CDK inhibition, Mcl-1 modulation was 
not found to correlate with response in CLL patients [38]. 
Although data suggest that complete suppression of p-Rb 
upon dinaciclib treatment correlates closely with induction 
of apoptosis in solid tumor cell lines and xenograft models 
[27–29], we could not consistently demonstrate such a rela-
tionship between p-Rb inhibition and cell death in patients’ 
PBMC in vivo or in primary leukemia cells or cell lines 
treated in vitro, including at the times when Mcl-1 down-
regulation was clearly present. This discrepancy may, in 
part, reflect heterogeneity of p-Rb expression in different 
leukemia cells, but also suggests that, at least in some leu-
kemias, the primary target of dinaciclib activity may not be 
CDK1/2. A similar observation was recently made using 
dinaciclib in rhabdomyosarcoma tumor xenograft models 
[30]. Thus, whether inhibition of CDK1/2 or CDK9 or both 
is required for dinaciclib activity is likely to depend on cel-
lular context.
Given that 2-h dinaciclib infusion had only transient 
effect on peripheral blast count, and given the observed 
pharmacokinetic and pharmacodynamic data, we per-
formed in vitro studies on leukemia cells and demonstrated 
that prolonged exposures to dinaciclib (≥24 h), at concen-
trations (≤200 nM) that are far below the Cmax (>4,000 
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nM) observed in the clinical study, caused more profound 
and persistent down-regulation of Mcl-1 and/or p-Rb 
across all cell lines/primary leukemia cells, leading to more 
effective cell kill. Preliminary PK data from clinical studies 
in solid tumors, using 8- and 24-h continuous infusion, sug-
gest that average dinaciclib concentrations of 200–1,031 
nM (7.4–50 mg/m2) and 82.3–184 nM (7.4–14.6 mg/m2) 
can be achieved, respectively [32]. Based on our in vitro 
data, these drug concentrations should be effective in kill-
ing leukemia cells.
With the exception of CLL [19, 20], single-agent CDK 
inhibitors have demonstrated very modest clinical anti-can-
cer activity in a broad range of tumors [17]. As shown in this 
study, dinaciclib has direct anti-leukemia cytotoxicity but 
effects are of short duration, suggesting that it needs to be 
combined with chemotherapy or other novel agents whose 
activity may be enhanced by dinaciclib-induced down-reg-
ulation of Mcl-1 in acute leukemias. Combination strate-
gies also need to take into account the cell cycle-modulating 
impact of dinaciclib; this approach has been effective for 
flavopiridol given in timed sequence with cytarabine and 
mitoxantrone in leukemia patients [22–26]. The observation 
that longer exposure times produce more effective cell kill 
in vitro and the effectiveness of weekly dinaciclib adminis-
tration in CLL [37] support pharmacologically driven stud-
ies that may optimize dinaciclib both as a single agent and 
as part of combination strategies in acute leukemias.
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